<DOC>
	<DOCNO>NCT00923273</DOCNO>
	<brief_summary>Background : The drug pemetrexed use treat non-small cell lung cancer ( NSCLC ) respond standard therapy recur standard therapy ; however , 9 100 patient respond pemetrexed . Sirolimus drug block protein cell call mammalian target rapamycin ( mTOR ) . In cancer cell , mTOR active , allow cell grow uncontrollably . This protein unusually active many case NSCLC . By block activity mTOR , sirolimus may make cancer cell responsive treatment pemetrexed . Objectives : To determine sirolimus combination pemetrexed safe well tolerated patient NSCLC . To determine high safe dose pemetrexed combine sirolimus . To look ability sirolimus pemetrexed fight NSCLC . To learn body eliminate sirolimus pemetrexed . Eligibility : Patients 18 year age old NSCLC whose disease respond standard therapy recur treatment standard therapy . Design : Biopsy treatment start , tumor easy reach bronchoscopy do needle biopsy . This procedure optional . Drug treatment , follow : - Day 1 : Intravenous ( vein ) infusion pemetrexed . Small group ( 3 6 ) patient give pemetrexed certain dose level . If first group experience significant side effect , next group receive high dose . This continue succeed group five dose level maximum tolerate study dose ( high dose patient give safely ) determine . - To lessen side effect pemetrexed , patient also receive Vitamin B12 injection every 21 day , folic acid tablet daily , dexamethasone tablet twice day day , day , day pemetrexed infusion . - Days 1-21 : Sirolimus tablet mouth . Evaluations treatment period : - History physical examination , blood urine test , electrocardiogram . - Disease evaluation compute tomography ( CT ) , positron emission tomography ( PET ) magnetic resonance scan ( MRI ) scan ... .</brief_summary>
	<brief_title>Sirolimus Pemetrexed Treat Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Background : - Lung cancer deadly cancer due late stage diagnosis intrinsic resistance chemotherapy . - Pemetrexed well tolerate Food Drug Administration ( FDA ) -approved second line chemotherapeutic agent 9 % response rate . - Increasing efficacy pemetrexed could provide clinical benefit patient refractory NSCLC . - Inhibition phosphoinositide 3-kinase ( PI3K ) /protein kinase B ( Akt ) /mTOR pathway may increase response chemotherapy . - Combining sirolimus , mTOR inhibitor , pemetrexed could improve patient outcome . Objectives : - Determine safety , tolerability , pharmacokinetics ( PKs ) , maximum tolerate dose ( MTD ) combination sirolimus pemetrexed subject NSCLC subject activation Akt/mTOR pathway . - Determine clinical response rate MTD sirolimus plus pemetrexed NSCLC subject . - Determine effect sirolimus activation PI3K/Akt/mTOR pathway peripheral blood mononuclear cell ( PBMCs ) and/or tumor tissue , determine metabolic change use PET scan , measure PKs . Eligibility : - Adults refractory relapse NSCLC regardless mTOR pathway activation permit enroll trial . Design : - Phase I follow Phase II study - For phase I/II subject , documentation mTOR pathway activation mandatory . If accessible , tissue obtain baseline follow two cycle therapy time progression , whichever occur first . Tumor tissue obtain baseline two cycle therapy time progression , whichever occur first . All subject pathway analysis use PBMCs baseline , day 8 every two cycle therapy time progression , whichever occur first . Cycle 1 28 day length others 21 day . - Each dose level incorporate lead-in period sirolimus alone allow correlation dose level , pharmacokinetics , biologic effect . - The phase I portion study 5 dose cohort begin FDA approve dos agent . There 3 dose escalation sirolimus 2 pemetrexed . Up 30 subject may enroll phase I study . - The Phase II portion utilize MTD Phase I enroll 60 subject . - Sirolimus administer mouth daily , pemetrexed administer intravenously every 21 day unacceptable toxicity disease progression . - Clinical imaging ( CT MRI ) PET CT obtain baseline two cycle treatment . Clinical imaging perform every two cycle disease progression .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Histologically documented non small cell lung cancer ( NSCLC ) confirm Laboratory Pathology Clinical Center/National Institutes Health ( NIH ) Laboratory Pathology National Naval Medical Center ( NNMC ) . 2 . Tumor biopsy request study subject unless procedure pose great risk . If subject decline , may still participate study . We ask subject undergo biopsy provide 6 unstained slide tissue block archive tissue immunohistochemistry ( IHC ) evaluation . Tumors subject enrol phase II portion study analyze retrospectively demonstrate mammalian target rapamycin ( mTOR ) activation assess immunohistochemistry fresh biopsy . mTOR activation define use distribution intensity stain phosphorylation mTOR , downstream substrate S6 kinase ( S6K ) , S6 . Standard operate procedure ( SOPs ) describe acquisition handle PBMCs tissue outline appendix 10.3 10.4 . At minimum , total score ( sum intensity distribution score ) 2 phosphoS6 phosphomTOR ( S2448 ) mTOR require determine mTOR active . Either measurement sufficient ascertain mTOR active . Measurement phosphorylation Akt , factor 4E binding protein 1 ( 4EBP1 ) , total level thymidylate synthase ( TS ) also measure , part eligibility requirement . In event limited tissue availability , stain prioritized follow : S6 , mTOR , S6K , Akt ( S473 ) , Akt ( T308 ) , TS . Phosphorylation S6 correlate closely mTOR activity , phosphorylation mTOR S2448 best predicts response sirolimus . 3 . Tissue time original diagnosis adequate enrollment study . Optional fresh tissue biopsy must obtain AFTER recent chemotherapy ( include small molecule target therapy ) radiation therapy . Tumors biopsied percutaneously ( without compute tomography ( CT ) /ultrasound guidance ) via bronchoscopy consider accessible compete risk factor coagulopathy , hypoxemia , unstable cardiovascular disease , uncontrolled pain , inability give inform consent . 4 . Individuals relapse NSCLC receive least one standard chemotherapeutic regimen eligible . Patients receive adjuvant chemotherapy relapse recur less equal 12 month completion chemotherapy eligible . Patients receive adjuvant chemotherapy relapse great 12 month completion chemotherapy receive frontline therapy metastatic disease enrollment , individual initially present incurable disease chemotherapy naive . Individuals unwilling receive standard front line therapy metastatic lung cancer may enroll . 5 . Patients must receive chemotherapy , biological , radiation therapy 21 day prior protocol enrollment . All previous chemo radiation therapy induced toxicity must resolve grade 1 less prior enrollment . 6 . Because sirolimus may affect efficacy hormonal birth control via cytochrome P450 3A4 ( CYP 3A4 ) , study subject child bear potential must willing use barrier birth control receive sirolimus therapy 12 week discontinuation sirolimus . 7 . Patients must measurable disease phase II portion study . 8 . Age great equal 18 year age . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . 10 . An expected survival least 3 month . 11 . Patients must capacity provide informed consent demonstrate willingness comply oral regimen . 12 . Patients must normal organ marrow function define : Absolute neutrophil count great equal 1,500/mL . Platelets great equal 100,000/mL . Total bilirubin le 1.5 time upper limit institutional normal . Aspartate aminotransferase ( AST ) serum glutamic oxaloacetic transaminase ( SGOT ) less 2.5 time upper limit institutional normal . Alanine aminotransferase ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) less 2.5 time upper limit institutional normal . Creatinine Estimated creatinine clearance calculate use modification diet renal disease ( MDRD ) equation must great equal 60ml/min/1.73m^2 . The formula use MDRD : 186 time ( Scr ) ( 1.154 ) time ( Age ) ( 0.203 ) time ( 0.742 female ) time ( 1.212 African American ) Serum triglycerides less equal 2.5 time upper limit normal ; serum cholesterol less equal 300 mg/dl ( include subject familial acquire hyperlipidemia ) . 13 . Subjects steroid must stable taper dose less equal 20 mg/day prednisone ( equivalent dose another glucocorticoid ) least one week prior study entry . EXCLUSION CRITERIA : 1 . Human immunodeficiency virus ( HIV ) positive patient . 2 . Pregnant lactating woman . 3 . Patients receive pemetrexed previously Phase 1 . Patients prior pemetrexed eligible Phase 2 . 4 . Patients prior therapy mTOR inhibitor sirolimus analogue within six month . 5 . Any concurrent therapy chemotherapeutic agent biologic agent radiation therapy . 6 . Subjects brain metastasis may participate metastasis asymptomatic . Subjects ineligible brain metastasis symptomatic . 7 . Patients follow drug modulate CYP3A4 replace medication equivalent medication period study : amprenavir , atazanavir , bromocriptine , cimetidine , clarithromycin , clotrimazole , cyclosporine , danazol , diltiazem , erythromycin , fluconazole , fosamprenavir , HIV protease inhibitor , indinavir , itraconazole , ketoconazole , metoclopramide , nefazodone , nelfinavir , nicardipine , nifedipine , ritonavir , saquinavir , telithromycin , troleandomycin ( TAO ) , verapamil , voriconazole , nevirapine , rifampicin , rifampin , rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital , St. John 's Wort . 8 . Subjects take non steroidal antiinflammatory agent unable stop replace agent 5 day prior 2 day pemetrexed eligible . 9 . Patients receive live vaccine past 21 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Pemetrexed</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>mTOR Inhibitor</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>